Monogenic diabetes was identified as a separate domain of diabetes, which is a rather generic representation of diseases characterized by hyperglycemia. It was then indicated that the differential diagnosis of such conditions is based on the genetic testing of the patients as well as identification of the specific gene that is mutated. The concept of integrative application of pharmacogenomics and personalized medicine for its treatment was proposed after the realization of the fact that the pathophysiology and therapeutic efficacy of the subsequent treatment methods depend upon the gene which is mutated. The article presents a concise overview of the need of research and development of personalized medicine based approaches for the treatment of monogenic diabetes.
All Published work is licensed under a Creative Commons Attribution 4.0 International License
Copyright © 2019 All rights reserved. iMedPub LTD Last revised : August 24, 2019